Health Care Ramifications of Pervasive Direct-to-Consumer Prescription Drug Advertising

Direct-to-consumer (DTC) advertisements for prescription drugs are an enduring feature of the US media landscape. These ads are costly (>$8 billion expended by drug manufacturers in 2023), legally protected, and tightly regulated in theory but less so in practice. DTC ads are well-established in magazines and television, with recent encroachment into social media and telehealth. Many ads rely on emotional appeals and captivating visuals, while few ads provide quantitative information on drug benefits and harms. Research shows that DTC advertising increases consumer awareness, drives prescription requests by patients, promotes prescribing by clinicians, and increases pharmaceutical expenditures. Based on limited data, effects on prescribing quality are mixed. Legal constraints notwithstanding, a case for more energetic regulation of DTC advertising can be made on normative, empirical, and logical grounds. Three broad strategies are recommended: (a) increased scrutiny, achieved by better funding of the US Food and Drug Administration and creative deployment of new technologies, including artificial intelligence; (b) moratoria on advertising for new, incompletely tested, or particularly hazardous drugs; and (c) selective prohibition of ads for specialty drugs that are almost universally prescribed by bona fide experts.